Table 1.

Patient characteristics

Wild-type EGFR (n = 221)Mutated EGFR (n = 70)P
Age
    Median6562
    Mean6361
    Range30-8541-85
Sex
    Male70 (32%)27 (39%)
    Female151 (68%)43 (61%)0.31
Stage at presentation
    I87 (39%)16 (23%)
    II11 (5%)2 (3%)
    III29 (13%)12 (17%)
    IV94 (43%)40 (57%)
Histology
    Adenocarcinoma105 (48%)35 (50%)
    AWBF79 (36%)24 (34%)
    BAC20 (9%)4 (6%)
    Adenosquamous4 (2%)1 (1%)
    Squamous4 (2%)1 (1%)
    Other9 (4%)5 (7%)
Smoking
    Former131 (59%)30 (43%)
    Current54 (24%)2 (3%)
    Never36 (16%)38 (54%)0.0001
Smoking history
    Never36 (16%)38 (54%)
    ≤515 (7%)7 (10%)
    6-1013 (6%)11 (16%)
    11-156 (3%)2 (3%)
    16-2518 (8%)2 (3%)
    26-5062 (28%)3 (4%)
    51-7527 (12%)1 (1%)
    >7529 (13%)2 (3%)
    Unknown15 (7%)4 (6%)
Race/ethnicity
    Asian3 (1%)7 (10%)0.002
    African American8 (4%)6 (9%)0.10
    Hispanic2 (1%)1 (1%)
    White/non-Hispanic204 (92%)55 (79%)
    Not reported5 (2%)1 (1%)
Treated with EGFR TKI
    Yes50 (23%)34 (49%)
    No171 (77%)36 (51%)
  • Abbreviations: BAC, bronchioloalveolar carcinoma; AWBF, adenocarcinoma with bronchioloalveolar carcinoma features.